Iceland· IS-EU/1/13/894/001-002
Sovaldi
A sofosbuvir product containing sofosbuvirum inn, registered in Iceland by Gilead Sciences Ireland UC*. The same ATC class is registered in 13 of our 19 countries.
Checked against Icelandic Medicines Agency (Iceland) on
Informational only — not a medical device.
Where it is registered
Sofosbuvir is registered in 13 of 19 countries.
Countries holding a registration under ATC J05AP08 (sofosbuvir), each read from that country’s own register.
- This record: Iceland, from Icelandic Medicines Agency (Iceland)
- 8 of them publish a price we can compare per daily dose
Sofosbuvir · ATC J05AP08
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of sofosbuvir costs, country by country.
Normalised to the WHO defined daily dose (0.4 g), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Sofosbuvir · price per daily dose (0.4 g)
USD · FX 28 Sept 2026
- FR France$0.30
The record
At a glance
Icelandic Medicines Agency (Iceland)- Active substance
- Sofosbuvirum INN
- Manufacturer
- Gilead Sciences Ireland UC*
- Country
- Iceland (IS)
- ATC code
- J05AP08
- ATC class
- Sofosbuvir
- Defined daily dose
- 0.4 g, O
- Reimbursed
- Not published by this register
- Source register
- Icelandic Medicines Agency (Iceland)
- Last checked
- September 29, 2026
Packs & prices · 1
1 priced- ean06257528 stk x1 glasISK 2333829
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
10 interactions on record for sofosbuvir.
Graded by severity as the source publishes them — 4 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Sofosbuvir · interactions on record
10 records
- 4 severe
- 5 moderate
- 1 minor
Most severe, free to view
- LorlatinibL01ED05severe
- LorlatinibL01XE44severe
- EnzalutamideL02BB04severe
- ApalutamideL02BB05severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Sofosbuvir in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaSOVALDIGilead Sciences Ireland UC, Carrigtohill
- SwitzerlandSovaldi 400 mg, FilmtablettenGilead Sciences Switzerland Sàrl
- SpainSOVALDI 400mg comprimidos recubiertos con peliculaGilead Sciences Ireland Unlimited Company
- FinlandSovaldiGilead Sciences Ireland UC
- FranceSOVALDI 400 mg, comprimé pelliculéGILEAD SCIENCES IRELAND UC (IRLANDE)
- IrelandSovaldi 400 mg film-coated tabletsGilead Sciences Ireland UC
- NetherlandsSovaldi 400 mg filmomhulde tablettenGilead Sciences Ireland UC
- NorwaySovaldiGilead Sciences Ireland UC
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Liechtenstein · Sovaldi
- Norway · Sovaldi
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Icelandic Medicines Agency (Iceland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/b75505fe-af3d-4cab-9663-e464d889d7f2 GET /v1/drugs/b75505fe-af3d-4cab-9663-e464d889d7f2?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Filmuhúðuð tafla",
"source": "lyfjastofnun",
"atc_raw": "J05AP08",
"marketed": true,
"strength": "400 mg",
"ma_number": "EU/1/13/894/001-002",
"substance": "Sofosbuvirum INN",
"other_info": "Ávísun lyfsins er bundin við sérfræðinga í smitsjúkdómum, meltingarfærasjúkdómum með sérþekkingu á lifrarsjúkdómum, barnasmitsjúkdómum, barnameltingarfærasjúkdómum og ávana- og fíknisjúkdómum.",
"legal_status": "(R Z) Sérfræðingsmerkt (og lyfseðilsskylt)",
"ma_issued_serial": "41655"
}See everything about sofosbuvir.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.